Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lenalidomide
Drug ID BADD_D01253
Description Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.[A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.[A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity.[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma in selected patients.[L16028] Lenalidomide is available only under a special restricted distribution program.[A228708]
Indications and Usage Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Marketing Status Prescription
ATC Code L04AX04
DrugBank ID DB00480
KEGG ID D04687
MeSH ID D000077269
PubChem ID 216326
TTD Drug ID D0Q5NX
NDC Product Code 59572-415; 59572-402; 55488-0700; 0480-1242; 0480-1244; 14096-131; 65727-084; 0480-1246; 59572-420; 59116-4710; 59572-425; 53104-7720; 59572-410; 55111-911; 68554-0090; 71796-026; 0480-1243; 46708-927; 59572-405; 53104-7726; 54893-0061; 82245-0101; 65015-772
Synonyms Lenalidomide | 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione | 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)- | IMiD3 Cpd | CC 5013 | CC5013 | CC-5013 | Revlimid | Revimid
Chemical Information
Molecular Formula C13H13N3O3
CAS Registry Number 191732-72-6
SMILES C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Plasma cell myeloma recurrent16.23.02.006; 01.14.02.0060.028094%Not Available
Clear cell renal cell carcinoma16.08.02.004; 20.01.04.008--Not Available
Eye contusion06.11.01.011; 24.07.06.022; 12.01.04.0240.002316%Not Available
Anal squamous cell carcinoma16.13.05.002; 07.21.05.0040.000755%Not Available
Appendix cancer16.13.01.011; 07.21.01.0090.001158%Not Available
Small intestine adenocarcinoma07.21.01.015; 16.13.13.0010.001158%Not Available
Myeloma cast nephropathy20.05.03.018; 16.32.03.0240.004632%Not Available
Gastrointestinal polyp haemorrhage24.07.02.046; 16.05.03.003; 07.20.01.0110.001737%Not Available
Splenic thrombosis24.01.08.006; 01.09.02.0180.001158%Not Available
Eyelid rash23.03.13.020; 06.04.04.0170.001158%Not Available
Pulmonary pain22.02.04.0130.002895%Not Available
Chronic throat clearing22.02.05.0380.001158%Not Available
Graft versus host disease in gastrointestinal tract12.02.09.028; 10.02.01.059; 07.11.01.027--Not Available
Internal haemorrhage24.07.01.072--Not Available
Soft tissue sarcoma16.33.01.003; 15.09.03.021--Not Available
Burn oral cavity12.05.04.006; 07.11.01.0210.002316%Not Available
Lower respiratory tract congestion22.02.04.0100.001737%Not Available
Urinary tract discomfort20.02.03.0170.001158%Not Available
Tumour marker abnormal13.22.01.0160.001158%Not Available
Vein rupture24.03.02.032; 12.01.11.0110.001158%Not Available
Critical illness08.01.03.0650.000302%Not Available
End stage renal disease20.01.03.019--Not Available
Intracranial mass17.11.01.0170.002895%Not Available
Tongue discomfort07.14.02.0190.006948%Not Available
The 70th Page    First    Pre   70    Total 70 Pages